Canagliflozin and Digoxin Interaction
Drug interaction information between Canagliflozin and Digoxin.
Canagliflozin and Digoxin have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Canagliflozin and Digoxin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Canagliflozin can increase the amount of digoxin that stays in your body.
What To Do
Your doctor should monitor you closely to see if your digoxin dose needs to be adjusted.
FDA Label Information
Digoxin Clinical Impact: Canagliflozin increases digoxin exposure [see Clinical Pharmacology (12.3) ] . Intervention: Monitor patients taking INVOKANA with concomitant digoxin for a need to adjust the dosage of digoxin.
Canagliflozin Also Interacts With
- Rifampin moderate
- Phenytoin moderate
- Phenobarbital moderate
- Lithium minor
Digoxin Also Interacts With
- Nicardipine major
- Posaconazole major
- Sotalol moderate
- Dofetilide moderate
- Ivabradine moderate
Frequently Asked Questions
Can I take Canagliflozin and Digoxin together?
This is a minor interaction. Your doctor should monitor you closely to see if your digoxin dose needs to be adjusted.
How serious is the interaction between Canagliflozin and Digoxin?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Canagliflozin and Digoxin interact?
Canagliflozin can increase the amount of digoxin that stays in your body.
Understanding the Canagliflozin and Digoxin Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Canagliflozin belongs to the SGLT2 Inhibitor class and Digoxin belongs to the Cardiac Glycoside class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Canagliflozin can increase the amount of digoxin that stays in your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Canagliflozin has 5 total documented interactions on file in this dataset, and Digoxin has 120. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor you closely to see if your digoxin dose needs to be adjusted. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Canagliflozin or Digoxin based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.